Tianhua Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tianhua Ma has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Sheng Ding
New Cornerstone Science Laboratory, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
12 shared publications Dan Wang
New Cornerstone Science Laboratory, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
8 shared publicationsYuxia Zhang
New Cornerstone Science Laboratory, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
5 shared publicationsKezhang He
New Cornerstone Science Laboratory, School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China
4 shared publicationsPengcheng Tan
New Cornerstone Science Laboratory, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
4 shared publicationsPengqi Wang
Tsinghua University
4 shared publications
Latest Publications
- 14 October 2026
- Published by Springer Nature in Nature
- p. 1-12
Modelling mouse embryogenesis from chemically induced totipotent stem cells
- 14 October 2026
- Published by Springer Nature in Nature
- p. 1-12
Modelling mouse embryogenesis from chemically induced totipotent stem cells
- Open Access
- 30 September 2026
- Published by Springer Nature in Research Square
Cas9 nickase-mediated gene editing enables precise large-fragment integration with minimal byproducts
Precise installation of large DNA sequences remains constrained by the core logic of current genome-editing platforms. Canonical homology-directed repair (HDR) relies on double-strand breaks and long homology arms, whereas prime-editing-based approaches depend on pegRNA-encoded information and reverse transcription. Here we report Nickase-mediated Gene Editing (NKGE), a paired-nick strategy for precise genome writing that is mechanistically distinct from both paradigms. NKGE employs Cas9(H840A) nickases and paired sgRNAs to generate spatially defined target-site nicks, thereby creating localized single-stranded regions that support donor capture and seamless DNA installation using only ~17-bp terminal homology, without requiring double-strand breaks, long homology arms, reverse transcriptase, recombinases, or transposases. This design actively circumvents indel and off-target formation by leveraging the high-fidelity repair pathways associated with single-strand nicks. Across multiple genomic loci and human cell lines, NKGE supported precise insertion of DNA fragments up to 10 kb with minimal indels and negligible off-target integration. NKGE also retained substantial activity under cell-cycle arrest and consistently outperformed HDR, prime editing, Prime Assembly, and QuadPE for medium- to large-scale insertions under matched conditions. Together, these findings establish NKGE as a distinct route for precise genome writing and broaden the mechanistic and practical scope of therapeutic DNA installation.
- 30 September 2026
- Published by Springer Nature in Research Square
Open AccessCas9 nickase-mediated gene editing enables precise large-fragment integration with minimal byproducts
Precise installation of large DNA sequences remains constrained by the core logic of current genome-editing platforms. Canonical homology-directed repair (HDR) relies on double-strand breaks and long homology arms, whereas prime-editing-based approaches depend on pegRNA-encoded information and reverse transcription. Here we report Nickase-mediated Gene Editing (NKGE), a paired-nick strategy for precise genome writing that is mechanistically distinct from both paradigms. NKGE employs Cas9(H840A) nickases and paired sgRNAs to generate spatially defined target-site nicks, thereby creating localized single-stranded regions that support donor capture and seamless DNA installation using only ~17-bp terminal homology, without requiring double-strand breaks, long homology arms, reverse transcriptase, recombinases, or transposases. This design actively circumvents indel and off-target formation by leveraging the high-fidelity repair pathways associated with single-strand nicks. Across multiple genomic loci and human cell lines, NKGE supported precise insertion of DNA fragments up to 10 kb with minimal indels and negligible off-target integration. NKGE also retained substantial activity under cell-cycle arrest and consistently outperformed HDR, prime editing, Prime Assembly, and QuadPE for medium- to large-scale insertions under matched conditions. Together, these findings establish NKGE as a distinct route for precise genome writing and broaden the mechanistic and practical scope of therapeutic DNA installation.
- Open Access
- 20 July 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 281
Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression
UFMylation, a recently identified ubiquitin-like modification, is essential for cellular stress homeostasis, particularly endoplasmic reticulum (ER) stress regulation. However, its biological and therapeutic exploration has been hindered by the absence of potent small-molecule inhibitors. Here, we report the first discovery of two compounds targeting the UFMylation E3 ligase complex core protein DDRGK1: Osimertinib, originally designed as an EGFR T790M selective inhibitor, acting through a previously unrecognized covalent mechanism, and CP-24, a novel non-covalent inhibitor. Both compounds disrupt the DDRGK1-UFL1 interaction, globally suppress UFMylation, inhibit ER-phagy, and induce ER stress. In glioblastoma (GBM), pharmacological UFMylation inhibition markedly reduces tumor cell viability and sensitizes cells to Temozolomide and radiotherapy. Both compounds also exert strong immunomodulatory activity, promoting macrophage polarization toward an anti-tumor M1 state. In vivo, Osimertinib, benefiting from superior pharmacokinetics, significantly suppresses tumor growth in immunodeficient models and achieves tumor-free outcomes in 65% of immunocompetent mice. These tumor-free mice develop durable anti-GBM immune memory, rapidly clearing tumors upon rechallenge, an outcome unattainable by previous GBM treatments. Mechanistically, Osimertinib enhances anti-tumor immunity by promoting macrophage M1 polarization, T cell expansion, and reducing PD-1 protein levels. Collectively, our study introduces Osimertinib and CP-24 as valuable chemical probes for dissecting UFMylation biology and highlights Osimertinib’s potential for off-label use in EGFR-wildtype GBM. More broadly, we establish UFMylation inhibition as a dual-targeting therapeutic strategy that disrupts tumor survival pathways and reprograms the immune microenvironment, offering a promising avenue for durable GBM control.
- 20 July 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 281
Open AccessDual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression
UFMylation, a recently identified ubiquitin-like modification, is essential for cellular stress homeostasis, particularly endoplasmic reticulum (ER) stress regulation. However, its biological and therapeutic exploration has been hindered by the absence of potent small-molecule inhibitors. Here, we report the first discovery of two compounds targeting the UFMylation E3 ligase complex core protein DDRGK1: Osimertinib, originally designed as an EGFR T790M selective inhibitor, acting through a previously unrecognized covalent mechanism, and CP-24, a novel non-covalent inhibitor. Both compounds disrupt the DDRGK1-UFL1 interaction, globally suppress UFMylation, inhibit ER-phagy, and induce ER stress. In glioblastoma (GBM), pharmacological UFMylation inhibition markedly reduces tumor cell viability and sensitizes cells to Temozolomide and radiotherapy. Both compounds also exert strong immunomodulatory activity, promoting macrophage polarization toward an anti-tumor M1 state. In vivo, Osimertinib, benefiting from superior pharmacokinetics, significantly suppresses tumor growth in immunodeficient models and achieves tumor-free outcomes in 65% of immunocompetent mice. These tumor-free mice develop durable anti-GBM immune memory, rapidly clearing tumors upon rechallenge, an outcome unattainable by previous GBM treatments. Mechanistically, Osimertinib enhances anti-tumor immunity by promoting macrophage M1 polarization, T cell expansion, and reducing PD-1 protein levels. Collectively, our study introduces Osimertinib and CP-24 as valuable chemical probes for dissecting UFMylation biology and highlights Osimertinib’s potential for off-label use in EGFR-wildtype GBM. More broadly, we establish UFMylation inhibition as a dual-targeting therapeutic strategy that disrupts tumor survival pathways and reprograms the immune microenvironment, offering a promising avenue for durable GBM control.
- Open Access
- 11 November 2025
- Published by Wiley in Advanced Science
- Vol. 13 (6) , e11880
ALDOA‐Mediated Metabolic Reprogramming is a Targetable Vulnerability for Ferroptosis Sensitization in Cancer
Ferroptosis presents great potential for cancer therapy, either alone or in combination with classical therapy. However, inducing ferroptosis by targeting canonical ferroptosis suppressors that directly inhibit lipid peroxidation non‐selectively induces ferroptosis in both cancerous and normal cells, thereby limiting its therapeutic potential. In this study, it is revealed that aldolase A (ALDOA) reprograms lipid metabolism to resist ferroptosis in cancer cells and identifies ALDOA as a targetable vulnerability for ferroptosis sensitization. Cancer cells with ALDOA suppression exhibit increased susceptibility to ferroptosis—a response less obvious in normal cells. Mechanistically, ALDOA depletion induces significant accumulation of fructose 1,6‐bisphosphate in cancer cells, thereby enhancing autophagy‐dependent degradation of phospholipid‐modifying enzymes. These alterations increase the ratio of phospholipids containing pro‐ferroptotic polyunsaturated fatty acids over anti‐ferroptotic monounsaturated fatty acids, culminating in heightened ferroptosis sensitivity. Moreover, ALDOA inhibitors selectively promote ferroptosis in cancer cells, both in vitro and in vivo. Collectively, the findings reveal that ALDOA‐mediated metabolic reprogramming is a targetable vulnerability for ferroptosis sensitization in cancer.
- 11 November 2025
- Published by Wiley in Advanced Science
- Vol. 13 (6) , e11880
Open AccessALDOA‐Mediated Metabolic Reprogramming is a Targetable Vulnerability for Ferroptosis Sensitization in Cancer
Ferroptosis presents great potential for cancer therapy, either alone or in combination with classical therapy. However, inducing ferroptosis by targeting canonical ferroptosis suppressors that directly inhibit lipid peroxidation non‐selectively induces ferroptosis in both cancerous and normal cells, thereby limiting its therapeutic potential. In this study, it is revealed that aldolase A (ALDOA) reprograms lipid metabolism to resist ferroptosis in cancer cells and identifies ALDOA as a targetable vulnerability for ferroptosis sensitization. Cancer cells with ALDOA suppression exhibit increased susceptibility to ferroptosis—a response less obvious in normal cells. Mechanistically, ALDOA depletion induces significant accumulation of fructose 1,6‐bisphosphate in cancer cells, thereby enhancing autophagy‐dependent degradation of phospholipid‐modifying enzymes. These alterations increase the ratio of phospholipids containing pro‐ferroptotic polyunsaturated fatty acids over anti‐ferroptotic monounsaturated fatty acids, culminating in heightened ferroptosis sensitivity. Moreover, ALDOA inhibitors selectively promote ferroptosis in cancer cells, both in vitro and in vivo. Collectively, the findings reveal that ALDOA‐mediated metabolic reprogramming is a targetable vulnerability for ferroptosis sensitization in cancer.
- Open Access
- 29 May 2025
- Published by Springer Nature in Research Square
Discovery of Hsp70-Mediated Lysosomal Repair as a Highly Specific Target for Senolysis
Senescent cells (SnCs) play a central role in aging and various age-related diseases, making their selective elimination a promising therapeutic strategy for extending lifespan and mitigating these conditions. However, the development of selective senolytic agents that exclusively target SnCs remains a challenge due to the absence of mechanisms that distinctly differentiate them from non-senescent cells (non-SnCs). In this study, we report a serendipitous discovery that Pifithrin-µ (PES), through its inhibition of Hsp70, exhibits highly selective senolytic activity. Mechanistic investigations revealed that SnCs harbor dysfunctional lysosomes with compromised membrane integrity—a vulnerability typically counteracted by the upregulation and lysosomal recruitment of Hsp70, which facilitates lysosomal repair by enhancing ceramide production. Inhibition of Hsp70 by PES selectively disrupts this repair mechanism, inducing catastrophic lysosomal membrane permeability (LMP) and triggering lysosome-dependent cell death (LDCD) specifically in SnCs. Moreover, PES treatment improved aging-related phenotypes and reversed lung fibrosis in mouse models of irradiation-induced accelerated aging and pulmonary fibrosis, respectively. These findings establish Hsp70 as a novel and transformative senolytic target and suggest that targeting the senescence-specific lysosomal repair pathway could provide a safer, more selective, and efficacious alternative to current senolytic strategies, which primarily target non-specific anti-apoptotic pathways.
- 29 May 2025
- Published by Springer Nature in Research Square
Open AccessDiscovery of Hsp70-Mediated Lysosomal Repair as a Highly Specific Target for Senolysis
Senescent cells (SnCs) play a central role in aging and various age-related diseases, making their selective elimination a promising therapeutic strategy for extending lifespan and mitigating these conditions. However, the development of selective senolytic agents that exclusively target SnCs remains a challenge due to the absence of mechanisms that distinctly differentiate them from non-senescent cells (non-SnCs). In this study, we report a serendipitous discovery that Pifithrin-µ (PES), through its inhibition of Hsp70, exhibits highly selective senolytic activity. Mechanistic investigations revealed that SnCs harbor dysfunctional lysosomes with compromised membrane integrity—a vulnerability typically counteracted by the upregulation and lysosomal recruitment of Hsp70, which facilitates lysosomal repair by enhancing ceramide production. Inhibition of Hsp70 by PES selectively disrupts this repair mechanism, inducing catastrophic lysosomal membrane permeability (LMP) and triggering lysosome-dependent cell death (LDCD) specifically in SnCs. Moreover, PES treatment improved aging-related phenotypes and reversed lung fibrosis in mouse models of irradiation-induced accelerated aging and pulmonary fibrosis, respectively. These findings establish Hsp70 as a novel and transformative senolytic target and suggest that targeting the senescence-specific lysosomal repair pathway could provide a safer, more selective, and efficacious alternative to current senolytic strategies, which primarily target non-specific anti-apoptotic pathways.
- Open Access
- 9 December 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Pharmacologically inducing regenerative cardiac cells by small molecule drugs
Adult mammals, unlike some lower organisms, lack the ability to regenerate damaged hearts through cardiomyocytes (CMs) dedifferentiation into cells with regenerative capacity. Developing conditions to induce such naturally unavailable cells with potential to proliferate and differentiate into CMs, that is, regenerative cardiac cells (RCCs), in mammals will provide new insights and tools for heart regeneration research. In this study, we demonstrate that a two-compound combination, CHIR99021 and A-485 (2C), effectively induces RCCs from human embryonic stem cell-derived TNNT2+ CMs in vitro, as evidenced by lineage tracing experiments. Functional analysis shows that these RCCs express a broad spectrum of cardiogenesis genes and have the potential to differentiate into functional CMs, endothelial cells, and smooth muscle cells. Importantly, similar results were observed in neonatal rat CMs both in vitro and in vivo. Remarkably, administering 2C in adult mouse hearts significantly enhances survival and improves heart function post-myocardial infarction. Mechanistically, CHIR99021 is crucial for the transcriptional and epigenetic activation of genes essential for RCC development, while A-485 primarily suppresses H3K27Ac and particularly H3K9Ac in CMs. Their synergistic effect enhances these modifications on RCC genes, facilitating the transition from CMs to RCCs. Therefore, our findings demonstrate the feasibility and reveal the mechanisms of pharmacological induction of RCCs from endogenous CMs, which could offer a promising regenerative strategy to repair injured hearts.
- 9 December 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessPharmacologically inducing regenerative cardiac cells by small molecule drugs
Adult mammals, unlike some lower organisms, lack the ability to regenerate damaged hearts through cardiomyocytes (CMs) dedifferentiation into cells with regenerative capacity. Developing conditions to induce such naturally unavailable cells with potential to proliferate and differentiate into CMs, that is, regenerative cardiac cells (RCCs), in mammals will provide new insights and tools for heart regeneration research. In this study, we demonstrate that a two-compound combination, CHIR99021 and A-485 (2C), effectively induces RCCs from human embryonic stem cell-derived TNNT2+ CMs in vitro, as evidenced by lineage tracing experiments. Functional analysis shows that these RCCs express a broad spectrum of cardiogenesis genes and have the potential to differentiate into functional CMs, endothelial cells, and smooth muscle cells. Importantly, similar results were observed in neonatal rat CMs both in vitro and in vivo. Remarkably, administering 2C in adult mouse hearts significantly enhances survival and improves heart function post-myocardial infarction. Mechanistically, CHIR99021 is crucial for the transcriptional and epigenetic activation of genes essential for RCC development, while A-485 primarily suppresses H3K27Ac and particularly H3K9Ac in CMs. Their synergistic effect enhances these modifications on RCC genes, facilitating the transition from CMs to RCCs. Therefore, our findings demonstrate the feasibility and reveal the mechanisms of pharmacological induction of RCCs from endogenous CMs, which could offer a promising regenerative strategy to repair injured hearts.
- Open Access
Reinforced identity confers cells with cancer hallmarks
Genetic alterations trigger tumorigenesis in a cell type-specific manner, but the biological basis for this, remains unclear. Here we define reinforced original cell identity established by interaction between genetic alterations and original cell type is a pivotal determinant of tumor development. Using AML-M5 MLL-AF9 as a model system, we demonstrated that MLL-AF9 enhanced key transcriptional factors (TFs) expression of promonocyte and cooperated with them to amplify their downstream programs for AML hallmarks. Interactions between MLL-AF9 and promonocyte endowed cancer cells with a reinforced promonocyte identity. Reinforced intrinsic cell identity also sustained cancer hallmarks across cancer types. Furthermore, we identified narciclasine, as an effective disruptor of reinforced promonocyte identity, effectively treating AML-M5 MLL-AF9 . This study not only identified reinforced cell identity as a fundamental tumor driver beyond genetic mutations but also offers a proof-of-concept for reinforced identity- targeted cancer therapy.
Open AccessReinforced identity confers cells with cancer hallmarks
Genetic alterations trigger tumorigenesis in a cell type-specific manner, but the biological basis for this, remains unclear. Here we define reinforced original cell identity established by interaction between genetic alterations and original cell type is a pivotal determinant of tumor development. Using AML-M5 MLL-AF9 as a model system, we demonstrated that MLL-AF9 enhanced key transcriptional factors (TFs) expression of promonocyte and cooperated with them to amplify their downstream programs for AML hallmarks. Interactions between MLL-AF9 and promonocyte endowed cancer cells with a reinforced promonocyte identity. Reinforced intrinsic cell identity also sustained cancer hallmarks across cancer types. Furthermore, we identified narciclasine, as an effective disruptor of reinforced promonocyte identity, effectively treating AML-M5 MLL-AF9 . This study not only identified reinforced cell identity as a fundamental tumor driver beyond genetic mutations but also offers a proof-of-concept for reinforced identity- targeted cancer therapy.
- Open Access
- 11 October 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Pharmacologically inducing regenerative cardiac cells by small molecule drugs
Summary Adult mammals, unlike some lower organisms, lack the ability to regenerate damaged hearts through cardiomyocytes (CMs) dedifferentiation into cells with regenerative capacity. Developing conditions to induce such naturally unavailable cells with potential to proliferate and differentiate into CMs, i.e., regenerative cardiac cells (RCCs), in mammals will provide new insights and tools for heart regeneration research. In this study, we demonstrate that a two-compound combination, CHIR99021 and A-485 (2C), effectively induces RCCs from human embryonic stem cell (hESC)-derived TNNT2+ CMs in vitro, as evidenced by lineage tracing experiments. Functional analysis shows that these RCCs express a broad spectrum of cardiogenesis genes and have the potential to differentiate into functional CMs, endothelial cells (ECs), and smooth muscle cells (SMCs). Importantly, similar results were observed in neonatal rat CMs both in vitro and in vivo. Remarkably, administering 2C in adult mouse hearts significantly enhances survival and improves heart function post-myocardial infarction. Mechanistically, CHIR99021 is crucial for the transcriptional and epigenetic activation of genes essential for RCC development, while A-485 primarily suppresses H3K27Ac and particularly H3K9Ac in CMs. Their synergistic effect enhances these modifications on RCC genes, facilitating the transition from CMs to RCCs. Therefore, our findings demonstrate the feasibility and reveal the mechanisms of pharmacological induction of RCCs from endogenous CMs, which could offer a promising regenerative strategy to repair injured hearts.
- 11 October 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessPharmacologically inducing regenerative cardiac cells by small molecule drugs
Summary Adult mammals, unlike some lower organisms, lack the ability to regenerate damaged hearts through cardiomyocytes (CMs) dedifferentiation into cells with regenerative capacity. Developing conditions to induce such naturally unavailable cells with potential to proliferate and differentiate into CMs, i.e., regenerative cardiac cells (RCCs), in mammals will provide new insights and tools for heart regeneration research. In this study, we demonstrate that a two-compound combination, CHIR99021 and A-485 (2C), effectively induces RCCs from human embryonic stem cell (hESC)-derived TNNT2+ CMs in vitro, as evidenced by lineage tracing experiments. Functional analysis shows that these RCCs express a broad spectrum of cardiogenesis genes and have the potential to differentiate into functional CMs, endothelial cells (ECs), and smooth muscle cells (SMCs). Importantly, similar results were observed in neonatal rat CMs both in vitro and in vivo. Remarkably, administering 2C in adult mouse hearts significantly enhances survival and improves heart function post-myocardial infarction. Mechanistically, CHIR99021 is crucial for the transcriptional and epigenetic activation of genes essential for RCC development, while A-485 primarily suppresses H3K27Ac and particularly H3K9Ac in CMs. Their synergistic effect enhances these modifications on RCC genes, facilitating the transition from CMs to RCCs. Therefore, our findings demonstrate the feasibility and reveal the mechanisms of pharmacological induction of RCCs from endogenous CMs, which could offer a promising regenerative strategy to repair injured hearts.
- 27 September 2024
- Published by Elsevier in Trends in Biotechnology
- Vol. 43 (1) , 206-219
Extended pegRNAs enhance the editing capability of Prime editing
- 27 September 2024
- Published by Elsevier in Trends in Biotechnology
- Vol. 43 (1) , 206-219
Extended pegRNAs enhance the editing capability of Prime editing